反応式
[N:1]1[C:10]2[C:5](=[CH:6][C:7]([CH2:11][C:12]3[N:16]4[N:17]=[C:18]([C:21](=O)[CH3:22])[CH:19]=[CH:20][C:15]4=[N:14][N:13]=3)=[CH:8][CH:9]=2)[CH:4]=[CH:3][CH:2]=1.[NH2:24][N:25]1[CH2:29][C:28](=[O:30])[NH:27][C:26]1=[O:31]>>[N:1]1[C:10]2[C:5](=[CH:6][C:7]([CH2:11][C:12]3[N:16]4[N:17]=[C:18](/[C:21](=[N:24]/[N:25]5[CH2:29][C:28](=[O:30])[NH:27][C:26]5=[O:31])/[CH3:22])[CH:19]=[CH:20][C:15]4=[N:14][N:13]=3)=[CH:8][CH:9]=2)[CH:4]=[CH:3][CH:2]=1参加物
3
実験手順
The title compound (20 mg, 51%) was synthesized from 1-(3-(quinolin-6-ylmethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)ethanone (30 mg, 0.1 mmol) and 1-aminoimidazolidine-2,4-dione (22.77 mg, 0.198 mmol) using the same procedure as described in the synthesis of example 37. 1H-NMR (400 MHz, DMSO-d6) δ ppm 11.44 (s, 1H), 9.05 (d, 1H), 8.70 (d, 1H), 8.32 (d, 1H), 8.12 (d, 2H), 7.98 (d, 1H), 7.87 (d, 1H), 7.77 (m, 1H), 4.83 (s, 2H), 4.54 (s, 2H), 2.40 (s, 3H). LCMS (method B): [MH]+=401.1, tR=1.64 min.
後処理
- customas described in the synthesis of example 37
出典と根拠
- ORDレコード
- ord-fbcd8ee8419c4c70a6e613b96f9e5e2d
- 出典データセット
- uspto-grants-2013_07
- 特許番号
- US08497368B2
関連ノート
読み込み中…